Biogen Inc vs Costco Wholesale Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Costco Wholesale Corporation trades at $948.07 (market cap $418.79B). The key difference: Costco Wholesale Corporation is far larger — about 13.9× Biogen Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | COST | |
|---|---|---|
Market Cap | $30.13B | $418.79B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $1.09K |
52-Week Low | $128.93 | $849.63 |
Enterprise Value | $37.20B | $406.93B |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Costco Wholesale Corporation (COST) trades at $948.43, down 0.45% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The stock shows strong fundamentals with revenue growth to $275.24 billion in 2025 and consistent earnings beats, though it missed Q1 2026 estimates. Recent news highlights membership fee hikes and robust March sales, while analyst consensus remains bullish with a $1,120 price target.
The outlook for COST is positive due to steady revenue growth and high analyst confidence, but risks include elevated valuation multiples and competitive pressures. Investment opportunity lies in its scalable business model and membership-driven profits, though investors should monitor earnings consistency and macroeconomic impacts on consumer spending.
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →